Son-Of-A-Bitch Mouse Solves Maze Researchers Spent Months Building | The Onion - America's Finest News Source - Sent Using Google Toolbar

Son-Of-A-Bitch Mouse Solves Maze Researchers Spent Months Building | The Onion - America's Finest News Source

Son-Of-A-Bitch Mouse Solves Maze Researchers Spent Months Building

April 19, 2008 | Issue 44•16

IOWA CITY, IA—University of Iowa neuroscientists studying spatial learning and the effects of stress on memory announced Tuesday that a little son-of-a-bitch mouse ruined an experiment on cognitive performance by effortlessly navigating a maze that researchers spent nearly a year designing and constructing.

The test subject, a common house mouse, briskly traversed the complicated wooden maze in under 30 seconds or, according to the study's final report, roughly 1/8,789,258 as long as it took the lab to secure funding for the experiment. According to researchers administrating the standard Y-maze test, the fucking bastard never even broke his stride during the first trial, always selecting the correct route while consistently avoiding blind dead-end alleys.

Enlarge Image Mouse

Above, researchers discuss plans for a new maze, since the prick of a mouse, right, destroyed their chances of making any new discoveries whatsoever about the nature of synaptical response.

"We were unable to observe any statistically significant behavioral changes in the subject, largely due to the fact that he was in such a goddamn hurry to finish the maze," said Dr. Richard Barret, who was forced to estimate the mouse's various reaction times after one of his assistants smashed the lab's stopwatch in anger. "Further analysis will be required to garner any useful knowledge regarding this particular mouse's neurological processes, his reflex response to stimuli, and how in the hell that stupid jerk reached the goal without screwing up once."

Despite attempts to condition the mouse by screaming directly into its face, the researchers reported that the subject smugly completed the second and third runs of the three- dimensional spatial task with ease. A videotape of the mouse pausing during the final run has been subjected to a thorough review by the lab in order to determine if one of the maze's obstacles managed to momentarily confuse the mouse or if the test subject was, in fact, gloating.

"Had we obtained any usable data, perhaps that information would have led to the development of a cure for neurodegenerative diseases like Alzheimer's," said Dr. William Eng, who led the team responsible for creating the maze. "What is unclear at this time is why this particular mouse had to be such a dick and render useless all the work we had put into this controlled behavioral experiment."

In order to create the maze, Eng hand-drew 15 drafts of the 5-foot by-6-foot wooden puzzle and utilized 3-D-modeling software before painstakingly gluing each 7-inch-tall piece of wood together. Even though Eng said the maze's interconnecting pathways were designed to provide a challenging series of obstructions to disorient the mouse, after completing the course, the subject reportedly ran back through to the starting line twice as fast.

"It is regrettable to spend such a tremendous amount of money studying mammalian neuropathways, only to have some hotshot mouse ruin everything," Eng said. "However, we have compiled substantial data on this species's ability to breeze right in and destroy an entire postdoctoral legacy."

Repeated trials yielded similar results, with the mouse performing equally well despite added variables of Dr. Eng trying to "scoot" it back with a pen and Dr. Barret tipping the entire maze upward 45 degrees. Additional attempts to deceive the mouse by placing a reward of cheese in an impassable section of the maze were also unsuccessful.

"Taking into account my past successful experiments with chimpanzees, it is my final analysis that we are dealing with one smart little fucker," said team member Dr. Russell Sutton, who has already applied for an additional grant to study cognitive learning in the same mouse. "I wonder if he'll be so smart without a functioning hippocampus."


Engineering Research News - Sent Using Google Toolbar

Engineering Research News

  Focused Ion Beam Biolithography - A New Approach for Biomolecule Patterning and Integrated Microfabrication  
iomicrodevices including biochips, BioMEMS, micro-total analysis system (μ-TAS), and lab-on-a-chip (LOC) are of great interest today, and much research is focused on smart technologies to fabricate such devices. A critical and often limiting step for the fabrication of
biomicrodevices is the immobilization and patterning of biomolecules and their perfect alignment to microstructures on the device. Some state-of-the-art biomolecule patterning techniques offer very high resolution but cannot give precise alignment between biomolecules and the underlying microstructures. Some techniques can potentially solve the alignment problem but they are "slow" and not suitable for mass fabrication. More importantly, the biomolecule patterning step is always separated from the microfabrication of structural elements, and is therefore not integrated.

Recently, our group developed a novel approach termed "Focused Ion Beam (FIB) Biolithography" for micro/nanopatterning of DNA and protein and its integration into microfabrication. FIB-Biolithography is a maskless approach which allows fast fabrication of various desired biomolecule patterns with high resolution and perfect alignment of biomolecule patterns with other microstructures. It is a top down approach, based on Ga+ ion FIB direct writing/milling of patterns. The desired DNA or protein is first covalently immobilized onto a substrate material (e.g. silicon/SiO2) and a gold film is deposited onto the immobilized biomolecules. The gold film acts as a protection layer for the FIB milling process where the pattern is created by FIB milling of biomolecules inclusive of the protective gold film at defined areas, and leaves behind non-milled areas of gold protected biomolecules, forming the desired pattern. After FIB milling the protective gold film is removed by treatment with a cyanide solution and a functional pattern of DNA or protein is created.

Figure 1 shows fluorescent micrographs and their corresponding fluorescence intensity plots of "stripe like" patterns of oligonucleotide, NeutrAvidin and anti-Mouse IgG fabricated by FIB-Biolithography after bioaffinity assays were performed. The biomolecules show high biofunctionality retention, biofunctional specificity, and uniformity after FIBBiolithography. So far, a feature size of better than 500 nm was demonstrated for FIB-Biolithography.

During the DNA and protein patterning, integrated microfabrication of structures was achieved simultaneously by FIB-Biolithography. Figure 2 shows SEM and AFM images of DNA (oligonucleotide) patterns and microchannels fabricated by FIB biolithography.


Contact person

Dr D Trau
Tel: 6516 8052,
Fax: 6872 3069
Email: bietrau@nus.edu.sg


As a result of the integrated biomolecule patterning and microfabrication, an inherently perfect alignment of the DNA patterns and the channels was achieved.

The FIB-Biolithography approach is fast, flexible and controllable, and can be applied for integrated biomolecule patterning and microfabrication in prefabricated structures or devices where precise local manipulation is needed. Importantly, this integrated approach may be combined with other existing FIB microfabrication techniques to fabricate microstructures of electrodes, sensors or conductive heaters etc, and potentially allows the fabrication of complex integrated biomicrodevices.




Biotech's Best And Worst | April 14, 2008 | By James Brumley - Investopedia Advisor - Sent Using Google Toolbar

Biotech's Best And Worst  |  April 14, 2008  | By James Brumley - Investopedia Advisor

Biotech's Best And Worst

April 14, 2008  | By James Brumley

On Friday I made a point about how all the major healthcare plan providers looked about the same: reasonable valuations, but frighteningly thin margins. With little room for error and growing government cutbacks, the prognosis was grim. Just to reassure myself that not all health-related companies were "a dime a dozen" I checked out the biotech industry looking for the same uniformity. Fortunately, I didn't find it.

Instead, I was pleased to find some outstanding biotech companies, that could still garner investor interest, as well as some companies that surprised me. I think both groups deserve a closer look today. I believe one is generally overvalued, and the other I believe is generally undervalued.

The Good
Medicis Pharmaceutical (NYSE:MRX): Medicis shares have lost more than one-third of their $33 value in the last 12 months, despite February's reporting of a 54% increase in fourth-quarter profits. Had the company given us a 2008 forecast above and beyond analyst's expectation, I may not even bother paying attention. However, its 2008 outlook was actually below analyst expectations, a bold move from a company with a sinking stock. And, it doesn't change the fact that the company is profitable as well as low-priced; profit margins over the last twelve months are 16% and the price-to-earnings ratio (P/E ratio) is about 17.

ViroPharma (Nasdaq:VPHM): A P/E ratio of almost 8 and profit margins consistently around 47%? Yes, there's a slowdown in sales of Vancocin. However, slower sales are still sales, and ViroPharma is still ringing the register quite well.

Amgen (Nasdaq:AMGN): You don't have to look too hard for reasons not to like Amgen. The FDA delayed its decision on Amgen's clotting-drug Romiplostim, the anemia drug Mircera is still part of a legal battle, and those are just a few of their headaches. Nevertheless, I'm still into a company that can sustain a top and bottom line even with all those issues. The P/E level is 15. (For more on the importance of the P/E Ratio to stock analysis, check out Investment Valuation Ratios: Price/Earnings Ratio.)

The Bad
 (Nasdaq:GENZ): It's actually not a bad company. I just can' t quite justify a stock valuation of 42-times earnings. The pipeline looks good. Genzyme has a pediatric leukemia drug called Clolar in the works, and an oral Gaucher's disease treatment also in development. Plus, Genzyme may resolve the manufacturing issues regarding its enzyme replacement treatment Myozyme. But, I can't help but wonder if the pipeline - none of which bears revenue - is inflating the stock price more than results.

Celgene (Nasdaq:CELG): When I saw the P/E ratio was 117, I thought it was a typo. It wasn't a typo though - nor was it a fluke. The stock's been a winner for year, but I don't think it's ever been justified by the company's results. Even the FDA's designation of Celgene's lung cancer drug Amrubicin as an "orphan drug" can't single-handedly bring the company's bottom line up to speed with the stock's price. Orphan drugs are treatments for rare diseases. This research receives tax breaks, and the drugs get extended patent protection.

Qiagen NV (Nasdaq:QGEN): Though not as inflated as Celgene, I can't get my hands around the idea of this company's stock trading at 73 times earnings. It's a biotech diagnostic supply company, that has somehow managed to grow the top line over the last three years but still shrink the bottom line (with or without Q4's charges).

The Bottom Line

You may be thinking the undervalued stocks have low P/E levels solely because those stocks have been getting beaten up. The opposite rings true for the overvalued stocks - they've been rallying despite being expensive. Why jump on a sinking ship, and why get off a floating one? The other dimension here is profits. Remember those? My "best" companies also have wide and reliable margins while my "worst" companies have oddly thin profit margins. That's got nothing to do with the stocks prices.

The bigger message, though, is to recognize that nothing lasts forever. In much the same way the market's sectors rotate their leadership role with one another, so too do the stocks within an industry. Eventually, companies with strong profits - rather than stories of potential - will push their way to the top of the heap.

To learn more about the cyclical nature of biotech stocks, read The Ups And Downs Of Biotechnology and Chasing Down Biotech Zombie Stocks.

By James Brumley

James Brumley is a freelance writer and registered investment advisor. He began his career as a broker with a major Wall Street firm, where fundamentals and long-term holding periods were core strategies. After that, he switched gears completely, becoming an analyst at a short-term trading newsletter that focused on technical analysis. He now manages client money using the best of both philosophies. His company, Bluegrass Portfolio Management, offers investors an opportunity to reap superior returns with minimized risk.

At the time of writing, James Brumley did not own shares in any of the companies mentioned in this article.

TheStreet.comTheStreet.com : Print Story - Feuerstein's Biotech-Stock Mailbag - Sent Using Google Toolbar

TheStreet.comTheStreet.com : Print Story - Feuerstein's Biotech-Stock Mailbag

Feuerstein's Biotech-Stock Mailbag

Adam Feuerstein

04/12/08 - 10:19 AM EDT

The big news this week was Takeda's $9 billion acquisition of Millennium Pharmaceuticals MLNM. The deal, or rather my perceived coverage of it, prompted a complaint from Rod R.

"So Adam, the biggest biotech rally in many months, like up 3% or better, and you have nothing to report? Maybe the hedgies are looking for virgin territory? It certainly deserves commentary. Got nothing?"

Rod, you need to subscribe to RealMoney, our subscription site! I was posting there all Thursday, discussing the Millennium takeout and the broader effect on the biotech sector.

In last week's Mailbag, I talked about the recent strength in the biotech sector, so clearly, the acquisition of Millennium, especially at a significant premium, helps further improve sentiment, if nothing else. Much of Thursday's gains in the sector, however, were given back Friday due to the broader-market pummeling.

For those without access to RealMoney (huh?), here's what I had to say this week.

Takeda is paying about 16 times 2008 (expected) sales of $570 million to buy Millennium. On a trailing basis, Takeda paid just under 17 times '07 sales. That's a big sales multiple either way you look at it. (Looking even further ahead, it's 13 times '09 sales expectations, still a hefty multiple.)

Millennium does have net operating losses, so I assume that brings down the "real" price a bit -- by how much, I'm not sure. As with the AstraZeneca AZN-MedImmune deal of 2007, which was also seen as pricey, overseas buyers appear to have no problem spending big to buy a piece of the U.S. biotech pie.

Naturally, the Takeda-Millennium deal will get tongues wagging about who's next in biotech to get bought out. Is a 50% takeout premium the new comp? What about 16 times sales?

If that's the case, and I don't really think you can count on it, U.S. Big Pharma, handicapped by the weak dollar and poor credit markets, will have a tough time matching up against their overseas competitors.

But maybe foreign drug firms really want our U.S. biotech assets, just like foreigners used to crave our commercial real estate and were willing to pay top dollar and then some.

All of this should be good news for investors in small- and mid-cap biotech stocks. Short-sellers have had their way with these companies this year, so perhaps the Millennium deal is enough to scare them a little bit.

Last week, I threw a bunch of potential M&A stocks out there, but of course, I didn't mention Millennium, which just continues my dismal track record for prognostication. But why not just forge ahead: If you use the Millennium sales multiple, or something even a bit lower, and apply that to stocks like Onyx Pharmaceuticals ONXX, United Therapeutics UTHR or ImClone IMCL -- all potential takeover targets -- you get some really big numbers.

Onward. Did everyone see the historic news out of Antigenics AGEN this week? The company received approval in Russia for Oncophage, its kidney cancer vaccine. This is the first approval for any cancer vaccine in the world. Wow! (And yes, I'm wearing my snarky pants.)

Of course, readers want to know what I think about Antigenics. Sandy P. writes: "Adam, you've been skeptical about cancer vaccines, but isn't this Antigenics approval in Russia a good thing? Why wouldn't the FDA approve Oncophage?"

The Russian approval of Oncophage is nonsense. The vaccine doesn't work, which was shown quite convincingly when the phase III study failed. Of course, that didn't stop Antigenics from fishing around the data for something positive in order to keep the company's lights on (and the CEO's paychecks rolling in).

This is the oldest biotech trick in the book, and the story always ends badly. The only twist here is the Russian approval, which Antigenics managed to parlay into some nice publicity last week. CNBC couldn't help itself, serving up steaming piles of Antigenics hype to the uninformed masses. And then you get misguided, hilarious columns like the one written by Michael Shulman for Seeking Alpha. Read it for comic relief.

The only thing you really need to know about Antigenics is that, less than 24 hours after announcing the Russian approval of Oncophage, the company went out and raised $21 million through a PIPE, or private placement sale, through Rodman & Renshaw. Shameless.

Oncophage is junk. The Russian approval is essentially a publicity stunt, aiming only to tap into this ongoing meme that the FDA is hostile to cancer vaccines, or that the regulators here really want cancer patients to die, which is why they won't approve cutting-edge, life-saving products like Oncophage.

What a bunch of garbage. Amusing garbage, but still stinky.

The disclosure this week that some patients using the inhaled insulin Exubera were diagnosed with lung cancer laid waste to shares of Nektar Therapeutics NKTR and MannKind MNKD.

However, Frank Z. is interested in Generex GNBT, which he says "has an asthma pump-like product that goes in the buccal cavity. It's already being sold in India and South America. Are you familiar with the company? Can they be the winners from this debacle?"

I don't know much about Generex, but from what I can glean from its Web site, the company is just starting phase III study of Generex Oral-lyn, which is an oral insulin spray that is absorbed in the lining of the mouth.

Interesting idea, I guess, in that this would avoid the potential safety problems found when insulin is absorbed in the lungs. There isn't anything new about buccal administration of drugs either; painkillers are administered in this way, too, for example.

However, and this is a big however, oral insulin of any kind is really a blue-sky concept at this point. Generex isn't the only company trying to accomplish this, and so far, there have been no winners, just lots of losers.

I'd stay away.

Naturally, my article Monday on Elan ELN, Wyeth WYE and their Alzheimer drug bapineuzumab caused a certain amount of anger, especially among the Elaniacs who spend way too much time on message boards.

Linda L., a lovely woman I'm sure, felt the need to vent:

This, your latest attempt at derailing Elan, is just incredibly sad. Do you really think people will listen to your rehashed nonsense, when those with true insight and scientific bona fides (Barron's, Chris Jenner of T. Rowe Price, William Tanner of Leerink Swann, David Faber of CNBC) illuminate the truth?

Elan is in the process of unleashing the most important drug in the history of biotech. Within that context, your puny denunciations sound breathtakingly childish, petty, and churlish. You've sold your (already faltering) credibility pretty cheaply. And to what end? You've achieved what may be a personal all-time low. Pitiful.

In all seriousness, I think my stories on Elan's use of the Neuropsychological Test Battery (NTB) to measure the efficacy of bapineuzumab have raised some important questions -- and highlight risks that weren't being discussed before.

Reasonable people can disagree, and ultimately, the data that we see later this year on bapineuzumab will hopefully tell us a lot about the potential of this drug to treat Alzheimer's, or not.

But I find people like Linda entirely unreasonable in that they're drinking the Elan Kool-Aid by the bucketful. It must be a tasty beverage, judging by the vitriol directed against anyone who dares question Elan's tactics or the potential of babineuzumab. (The same goes for its multiple sclerosis drug Tysabri.)

Elan is the textbook definition of a cult stock. And for natural-born skeptics like me, cult stocks are the most fun to cover. So, Linda, thanks for sharing.

Let's close this week's Mailbag with a note from Pir M. "Could you please comment on the outlook for Pozen's POZN Treximet i.e. the possibility for approval and stock outlook?"

The FDA is expected to issue an approval decision by April 15 on Treximet, which is Pozen's migraine drug being developed in partnership with GlaxoSmithKline GSK.

I touched on Treximet in a previous Mailbag, and unfortunately, the drug's fate has gotten cloudier as we get closer to the FDA decision.

Honestly, I don't know what the agency is going to do with this one. If you force me to go one way or the other, I'd have to be very cautious, if for no other reason that Pozen's track record with the FDA is lousy, and these days, the agency doesn't seem too eager to approve drugs with dangling question marks.

Would it surprise anyone if the FDA punts, deciding to delay a decision past April 15? Not me.

If you do own Pozen and believe Treximet will be approved next week, I'd hope you're appropriately hedged, just in case the FDA decision goes the other way or is delayed yet again.

New Preclinical Data Show Significant Anti-Tumor Activity Associated With Infinity's Hedgehog Antagonist IPI-926 - Sent Using Google Toolbar

New Preclinical Data Show Significant Anti-Tumor Activity Associated With Infinity's Hedgehog Antagonist IPI-926

You must have Javascript enabled to view this site. Please enable Javascript in your browser and reload the page.
Welcome, null
Business Leaders
C-Suite Sit Down
Market Overview
Mutual Funds & ETFs
Health Care
Real Estate
Personal Finance
Personal Finance
Small Business
Women in Business
Financial Planning
Personal Agenda
Real Estate & Mortgage
Family & Estates
College & Education
Lifestyle & Money
Health & Insurance
Travel & Lifestyle
Consumer & Debt
Career Center
Personal Technology
Tools & Calculators
On Topic
Our Team
Our Team
On Air
My Money
Sunday, Apr. 13 2008

New Preclinical Data Show Significant Anti-Tumor Activity Associated With Infinity's Hedgehog Antagonist IPI-926

Rated by 3 people
Rate This  
E-mail this Story
Digg It StumbleUpon Newsvine Reddit
Email this Article

Want to send this article to a friend? Enter both their email address and yours and we'll email a link to this article to them.

Enter thier e-mail address:

Enter your e-mail address:

View Archives

SAN DIEGO, Calif. and CAMBRIDGE, Mass., Apr 13, 2008 (PrimeNewswire via COMTEX) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that preclinical studies evaluating IPI-926, Infinity's novel Hedgehog pathway inhibitor, demonstrated that the compound has excellent pharmaceutical properties in vivo, including oral bioavailability, potent inhibition of the Hedgehog pathway, and long plasma and tumor half-life. Notably, in a novel mouse model of medulloblastoma, once-daily dose administration of IPI-926 resulted in 100 percent survival during the treatment period. These data were reported in an oral presentation today by Melissa Pink, a research investigator at Infinity, during the Annual Meeting of the American Association of Cancer Research (AACR) in San Diego, California.

IPI-926 is a novel, proprietary derivative of the natural plant product cyclopamine that binds to the Smoothened receptor to inhibit the Hedgehog pathway. When abnormally activated in adults, the Hedgehog pathway is believed to play a central role in allowing the proliferation and survival of certain cancer-causing cells, including those implicated in certain deadly cancers such as pancreatic cancer, prostate cancer, small cell lung cancer, breast cancer, and certain brain cancers.

"These promising new data show that once-daily oral administration of IPI-926 achieves therapeutic levels in plasma and tumors in preclinical models," stated Vito Palombella, Ph.D., vice president of drug discovery at Infinity. "By leveraging our synthetic and medicinal chemistry expertise, we improved the potency and optimized the pharmaceutical properties of cyclopamine, an existing natural antagonist of the Hedgehog pathway, through the discovery of IPI-926. Based on the preclinical data we are sharing at AACR on the potency, half-life, and in vivo anti-tumor activity of IPI-926, we believe that it has the potential to be a best-in-class Hedgehog pathway antagonist."

IPI-926 is a potent and selective inhibitor of the Hedgehog pathway in preclinical models. Infinity used a novel mouse model of medulloblastoma developed in the laboratory of Neil Watkins, M.B.B.S., Ph.D., assistant professor of oncology at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, to evaluate the activity of IPI-926 in vivo. Evaluation of the pharmacokinetics and pharmacodynamics of IPI-926 in this model demonstrated that the compound has excellent oral bioavailability, a long plasma half-life and duration of action, and good distribution to tumor tissue. In addition, daily oral administration of IPI-926 led to a dose-dependent inhibition of tumor growth, with tumor regression seen at higher doses. In a similar study, once-daily administration of oral IPI-926 resulted in a 100 percent survival while on treatment and median overall survival of 48 days, a four-fold increase over the 12 days seen in the vehicle-treated group.

Julian Adams, Ph.D., president of research and development and chief scientific officer at Infinity, added, "The Hedgehog pathway is implicated in medulloblastoma and many other very aggressive cancers. We believe that these and other data being presented this week at AACR provide a strong scientific rationale for clinical development of IPI-926 in several different types of cancer. We look forward to completing our investigational new drug-enabling studies and initiating human clinical trials later this year."

About IPI-926

IPI-926 is a novel, proprietary derivative of the natural plant product cyclopamine that binds to the Smoothened receptor to inhibit the Hedgehog pathway. In preclinical studies, IPI-926 has shown potent and selective inhibition of the Hedgehog pathway and attractive pharmacological properties, including oral bioavailability and extended half-life. IPI-926 has demonstrated biological activity in multiple preclinical animal models of cancer. Infinity anticipates commencing clinical trials of IPI-926 in the second half of 2008.

About the Hedgehog Signaling Pathway

The Hedgehog signaling pathway is normally active during embryonic development in regulating tissue and organ formation. When abnormally activated in adults, however, the Hedgehog pathway is believed to play a central role in allowing the proliferation and survival of certain cancer-causing cells, including in certain deadly cancers such as pancreatic cancer, prostate cancer, small cell lung cancer, breast cancer, and certain brain cancers. In addition, recent evidence also points to an important potential role for the Hedgehog pathway in cancer stem cells. Cancer stem cells are progenitor cells suspected to be primarily responsible for tumor growth, survival, and metastasis, despite treatment with conventional chemotherapeutic agents.

About Infinity Pharmaceuticals, Inc.

Infinity is an innovative cancer drug discovery and development company that is seeking to leverage its strength in small molecule drug technologies to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions. For more information on Infinity, please refer to the company's website at http://www.infi.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding the utility of Hedgehog pathway inhibition to treat various types of cancer and future clinical trial activity for IPI-926. Such statements are subject to numerous factors, risks, and uncertainties that may cause actual events or results to differ materially from Infinity's current expectations. For example, there can be no guarantee that IPI-926 will successfully complete necessary preclinical and clinical development phases. In particular, management's expectations could be affected by risks and uncertainties relating to: results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities and investigational review boards at clinical trial sites; Infinity's ability to obtain additional funding required to conduct its research, development, and commercialization activities; unplanned cash requirements and expenditures; and Infinity's ability to obtain, maintain, and enforce patent and other intellectual property protection for its Hedgehog pathway inhibitors, including IPI-926. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" included in Infinity's annual report on Form 10-K for the year ended December 31, 2007, as filed with the Securities and Exchange Commission on March 14, 2008. Further, any forward-looking statements contained in this press release speak only as of the date hereof, and Infinity expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.


This news release was distributed by PrimeNewswire, www.primenewswire.com

SOURCE: Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals, Inc.            Monique Allaire           (617) 453-1105           Monique.Allaire@infi.com            Pure Communications Inc.           Sheryl Seapy            (949) 903-4750           Sheryl@purecommunicationsinc.com
© Copyright 2008 PrimeNewswire, Inc. All rights reserved.  **********************************************************************  As of Wednesday, 04-09-2008 23:59, the latest Comtex SmarTrend® Alert,  an automated pattern recognition system, indicated an UPTREND on  04-08-2008 for INFI @ $7.44.  For more information on SmarTrend, contact your market data provider or go to www.mysmartrend.com  SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright © 2004-2008 Comtex News Network, Inc. All rights reserved.
View Archives
Click here to find out more!
Click here to find out more!
Click here to find out more!
Click here to find out more!
Advertise with usJobs at FOX Business Network.
Terms of usePrivacy Statement. For FOXBusiness.com technical issues write to foxbusinessonline@foxbusiness.com; for all other feedback, write to feedback@foxbusiness.com.
This material may not be published, broadcast, rewritten, or redistributed. 2008 FOX News Network, LLC. All rights reserved.
SmartMoney.com © 2008 SmartMoney. SmartMoney is a joint venture between Dow Jones & Company, Inc. and Hearst SM Partnership. All Rights Reserved. All quotes delayed by 20 minutes. Delayed quotes provided by Interactive Data Managed Solutions.  Historical prices and fundamental data provided by Hemscott, Inc. Mutual fund data provided by Lipper. Mutual Fund NAVs are as of previous day's close. Earnings estimates provided by Zacks Investment Research. Insider trading data provided by Thomson Financial. Upgrades and downgrades provided by Briefing.com.